Table 2.
Regulation of HIPPO-YAP pathway by lncRNA.
| Role | Target molecules | LncRNA | Disease | Role | Reference |
|---|---|---|---|---|---|
| Contribution to YAP | MST | LncRNA MAYA | Bone metastasis | The ROR1/HER3-LLGL2-MAYA-NSUN6 signaling axis methylates the MST1 site and eliminates MST1 kinase activity | (32) |
| Contribution to YAP | LATS | LncRNA SNHG9 | Breast Cancer | LncRNA SNHG9 promotes LATS1 liquid-liquid phase separation for oncogenic YAP | (33) |
| Contribution to YAP | LATS | HOTTIP | Osteosarcoma (OS) | HOTTIP catalyzes LATS2 promoter methylation | (34) |
| Contribution to YAP | YAP | LINC01559 | Pancreatic cancer | LINC01559 interacts with YAP protein and blocks YAP phosphorylation | (35) |
| Contribution to YAP | YAP | lncRNA USP2-AS1 | Colon Adenocarcinoma (COAD) | lncRNA USP2-AS1 binds YAP1 and decreases p-YAP (S127) | (36) |
| Contribution to YAP | YAP | B4GALT1-AS1 | Osteosarcoma (OS) | B4GALT1-AS1 recruits HuR to enhance the stability of YAP mRNA | (37) |
| Contribution to YAP | YAP | B4GALT1-AS1 | Colon Cancer | B4GALT1-AS1 binds to YAP and recruits YAP to the nucleus | (38) |
| Contribution to YAP | YAP | LncRNA-ATB | Hepatocellular carcinoma (HCC) | LncRNA-ATB reduces p-YAP expression and induces YAP nuclear translocation | (39) |
| Contribution to YAP | YAP | METTL3 | NSCLC | METTL3 promotes YAP mRNA translation and increases YAP mRNA stability by regulating the MALAT1-miR-1914-3p-YAP axis | (40) |
| Contribution to YAP | YAP | MALAT1 | Diabetic cardiomyopathy (DCM) | MALAT1 positively regulates the nuclear translocation of YAP by binding to CREB | (41) |
| Contribution to YAP | HIF-1α | LncRNA JPX | Intervertebral disc degeneration (IDD) | Overexpression of lncRNA JPX suppresses miR-18a-5p, upregulates HIF-1α and thereby inhibits Hippo-YAP pathway | (42) |
| Contribution to YAP | HIF-1α | LncRNA GHET1 | Triple-negative breast cancer (TNBC) | LncRNA GHET1 knockdown reduces the level of HIF-1α phosphorylation to retain YAP in the cytoplasm. | (43) |
| Suppression of YAP | YAP | Lnc-mi497RHG | Bladder Cancer | Lnc-mi497RHG synergistically inhibits Hippo-Yap and TGF-β pathways, especially attenuating the interaction between Yap and Smad3 | (44) |
| Suppression of YAP | YAP | GAS5 | Colorectal Cancer | GAS5 directly interacts with the YAP WW structural domain, promoting YAP phosphorylation and ubiquitin-mediated degradation | (45) |
| Suppression of YAP | LATS | LncRNA uc.134 | Hepatocellular carcinoma (HCC) | LncRNA uc.134 inhibits CUL4A-mediated LATS1 ubiquitination and increases YAPS127 phosphorylation | (46) |